Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic ImplicationsAnna N. Ligezka, Éva Morava, Karthik Muthusamy et al.|Annals of Neurology|2021Cited by 57
Interplay of Impaired Cellular Bioenergetics and Autophagy in PMM2-CDGAnna N. Ligezka, Tamás Kozicz|Genes|2023Cited by 19
Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directionsKarthik Muthusamy, Éva Morava, Judit Perez Ortiz et al.|Genetics in Medicine|2023Cited by 17
Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylationDiederik De Graef, Éva Morava, Anna N. Ligezka et al.|Molecular Genetics and Metabolism|2023Cited by 16
eP028: Neurological manifestations in PMM2 related congenital disorders of glycosylation (CDG): Insights into clinico-radiological characteristics and recommendations for follow-upKarthik Muthusamy, Eva Morava‐Kozicz, Anna N. Ligezka et al.|Genetics in Medicine|2022Cited by 0